What is Flint Rehab?
Flint Rehab operates at the intersection of medical technology and patient-centric care, specializing in clinically validated neurorehabilitation devices. The company's portfolio, which includes the FitMi full-body rehabilitation system and the MusicGlove hand therapy tool, is engineered to facilitate recovery from strokes, traumatic brain injuries, and other complex neurological conditions. By shifting the paradigm of rehabilitation from traditional clinical settings to the home environment, Flint Rehab addresses a critical gap in the healthcare continuum.
The company's market position is bolstered by its integration of speech and cognitive rehabilitation applications, creating a comprehensive ecosystem for neurological health. With a user base exceeding 10,000 home customers and widespread adoption across professional healthcare facilities, Flint Rehab has established itself as a trusted authority in the health-tech space, prioritizing evidence-based outcomes and user accessibility.
How much funding has Flint Rehab raised?
Flint Rehab has raised a total of $150K across 1 funding round:
Debt
$150K
Debt (2020): $150K with participation from PPP
Key Investors in Flint Rehab
PPP
Public-Private Partnership
What's next for Flint Rehab?
Looking ahead, the strategic deployment of this recent financing will likely focus on accelerating product development and expanding the company's footprint in the digital health market. As Flint Rehab transitions through this late-stage funding phase, the focus will shift toward enhancing its software-driven cognitive therapy offerings and potentially exploring new partnerships with healthcare providers to integrate its devices into standard post-acute care protocols.
The company is poised to leverage its established reputation to capture a larger share of the growing neurorehabilitation market. By maintaining its commitment to clinical efficacy and user-friendly design, Flint Rehab is set to define the next generation of home-based recovery, ensuring that patients receive high-quality, consistent therapy that drives measurable neurological improvement.
